‘Recombinant vaccine’ made with ‘surface antigen protein’ gene recombination technology
Domestic Corona 19 clinical trial…10 vaccines, 13 treatments (11 ingredients)
[팜뉴스=이권구 기자] On July 22, the Ministry of Food and Drug Safety (Director Kang-Rip Kim) approved the phase 1 clinical trial plan for safety and immunogenicity evaluation of the domestically developed COVID-19 vaccine ‘IN-B009’ (HK Innoen).
With this approval, the number of drugs currently undergoing clinical trials related to COVID-19 in Korea has become a total of 23 products, including 10 vaccines and 13 treatments (11 ingredients).
‘IN-B009 strain’ is a ‘recombinant vaccine’ made of the ‘surface antigen protein’ of the Corona 19 virus by genetic recombination technology. It was developed so that the protein can be well delivered into the cell by expressing it.
Overseas, US ‘NovaVax’ (Phase 3) and others are conducting clinical trials for a COVID-19 vaccine using genetic recombination technology.
Copyright holder © Farm News Unauthorized reproduction and redistribution prohibited